Wright Bonilla Quoted on DOJ Brief
November 5, 2010
BNA’s Patent, Trademark & Copyright Journal
Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BNA’s Patent, Trademark & Copyright Journal on November 5, 2010 titled “DOJ’s ‘Questionable Reinterpretation’ of DNA Patentability Disappoints Patent Community.” Wright Bonilla discusses the patent community’s backlash against a brief filed by the U.S. Department of Justice as a friend of the court in the Myriad case on the patentability of genetic materials. She cautions against an overreaction to the DOJ’s brief, stating that Myriad’s composition claims directed to cDNA are patent eligible. She adds that the DOJ brief asserts this patent eligibility and meets the threshold of Section 101 of the Patent Act.
Related News
July 24, 2025
In the News
Foley's Trial Team Featured Following Landmark Victory in Texas Trade Secret Case
Foley & Lardner LLP’s recent landmark appellate victory in a Texas trade secrets case is featured in the Texas Lawyer article, "Ruling Sets Precedent for Employment, Trade Secrets, Fiduciary Duty."
July 24, 2025
In the News
Gregory Husisian and David Simon on Tariff Evasion – 'Huge money at stake'
Foley & Lardner LLP partners Gregory Husisian and David Simon detailed the rise and risks of tariff evasion in the POLITICO article, "As Trump raises tariffs, companies find ways to cheat — and risk getting caught."
July 23, 2025
In the News
Aaron Maguregui on AI Scribes in Health Care – 'Technically, it's a third party listening'
Foley & Lardner LLP partner Aaron Maguregui shared insights on the growing applications for artificial intelligence across health care in the healthleaders article, “Is Your AI Scribe HIPAA-Compliant?“